{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:46:01Z","timestamp":1793295961512,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40263-026-01278-9","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:10:52Z","timestamp":1772212252000},"page":"657-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Potential of PCSK9 Inhibitors in Regulating Neuroinflammation in Acute Ischemic Stroke"],"prefix":"10.1007","volume":"40","author":[{"given":"Lanlan","family":"Pu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Joyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-1952","authenticated-orcid":false,"given":"Xiaofei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1546-7052","authenticated-orcid":false,"given":"Huijie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"10204","key":"1278_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/s0140-6736(19)30427-1","volume":"394","author":"M Zhou","year":"2019","unstructured":"Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145\u201358. https:\/\/doi.org\/10.1016\/s0140-6736(19)30427-1.","journal-title":"Lancet"},{"issue":"4","key":"1278_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/s1474-4422(18)30500-3","volume":"18","author":"S Wu","year":"2019","unstructured":"Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019;18(4):394\u2013405. https:\/\/doi.org\/10.1016\/s1474-4422(18)30500-3.","journal-title":"Lancet Neurol"},{"key":"1278_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010014","author":"A Jurcau","year":"2021","unstructured":"Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia\/reperfusion injuries: from pathophysiology to therapeutic strategies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms23010014.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1278_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06440-3","volume":"23","author":"W Lei","year":"2025","unstructured":"Lei W, Zhuang H, Huang W, Sun J. Neuroinflammation and energy metabolism: a dual perspective on ischemic stroke. J Transl Med. 2025;23(1):413. https:\/\/doi.org\/10.1186\/s12967-025-06440-3.","journal-title":"J Transl Med"},{"key":"1278_CR5","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3389\/fnins.2019.00770","volume":"13","author":"NN Nalivaeva","year":"2019","unstructured":"Nalivaeva NN, Rybnikova EA. Editorial: brain hypoxia and ischemia: new insights into neurodegeneration and neuroprotection. Front Neurosci. 2019;13:770. https:\/\/doi.org\/10.3389\/fnins.2019.00770.","journal-title":"Front Neurosci"},{"key":"1278_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.633610","volume":"15","author":"T Jover-Mengual","year":"2021","unstructured":"Jover-Mengual T, Hwang JY, Byun HR, Court-Vazquez BL, Centeno JM, Burguete MC, et al. The role of NF-\u03baB triggered inflammation in cerebral ischemia. Front Cell Neurosci. 2021;15:633610. https:\/\/doi.org\/10.3389\/fncel.2021.633610.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"1278_CR7","doi-asserted-by":"publisher","first-page":"C135","DOI":"10.1152\/ajpcell.00136.2018","volume":"316","author":"C Yang","year":"2019","unstructured":"Yang C, Hawkins KE, Dor\u00e9 S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol. 2019;316(2):C135-c153. https:\/\/doi.org\/10.1152\/ajpcell.00136.2018.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"1278_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","volume":"27","author":"X Huang","year":"2021","unstructured":"Huang X, Hussain B, Chang J. Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms. CNS Neurosci Ther. 2021;27(1):36\u201347. https:\/\/doi.org\/10.1111\/cns.13569.","journal-title":"CNS Neurosci Ther"},{"key":"1278_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1182621","volume":"17","author":"H Wang","year":"2023","unstructured":"Wang H, Li J, Zhang H, Wang M, Xiao L, Wang Y, et al. Regulation of microglia polarization after cerebral ischemia. Front Cell Neurosci. 2023;17:1182621. https:\/\/doi.org\/10.3389\/fncel.2023.1182621.","journal-title":"Front Cell Neurosci"},{"key":"1278_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1320271","volume":"14","author":"H Quan","year":"2023","unstructured":"Quan H, Zhang R. Microglia dynamic response and phenotype heterogeneity in neural regeneration following hypoxic-ischemic brain injury. Front Immunol. 2023;14:1320271. https:\/\/doi.org\/10.3389\/fimmu.2023.1320271.","journal-title":"Front Immunol"},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.2147\/jir.S461795","volume":"17","author":"X Shui","year":"2024","unstructured":"Shui X, Chen J, Fu Z, Zhu H, Tao H, Li Z. Microglia in ischemic stroke: pathogenesis insights and therapeutic challenges. J Inflamm Res. 2024;17:3335\u201352. https:\/\/doi.org\/10.2147\/jir.S461795.","journal-title":"J Inflamm Res"},{"issue":"2","key":"1278_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70229","volume":"31","author":"J Lv","year":"2025","unstructured":"Lv J, Jiao Y, Zhao X, Kong X, Chen Y, Li L, et al. Examining the impact of microglia on ischemic stroke with an emphasis on the metabolism of immune cells. CNS Neurosci Ther. 2025;31(2):e70229. https:\/\/doi.org\/10.1111\/cns.70229.","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"1278_CR13","doi-asserted-by":"publisher","first-page":"s125","DOI":"10.1007\/s12975-012-0174-9","volume":"3","author":"MD Hammond","year":"2012","unstructured":"Hammond MD, Ai Y, Sansing LH. Gr1+ macrophages and dendritic cells dominate the inflammatory infiltrate 12 hours after experimental intracerebral hemorrhage. Transl Stroke Res. 2012;3(1):s125\u201331. https:\/\/doi.org\/10.1007\/s12975-012-0174-9.","journal-title":"Transl Stroke Res"},{"issue":"12","key":"1278_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2174\/1570159x18666200528143301","volume":"18","author":"T Okada","year":"2020","unstructured":"Okada T, Suzuki H, Travis ZD, Zhang JH. The stroke-induced blood-brain barrier disruption: current progress of inspection technique, mechanism, and therapeutic target. Curr Neuropharmacol. 2020;18(12):1187\u2013212. https:\/\/doi.org\/10.2174\/1570159x18666200528143301.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1278_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00516","volume":"22","author":"S Sasannia","year":"2025","unstructured":"Sasannia S, Leigh R, Bastani PB, Shin HG, van Zijl P, Knutsson L, et al. Blood-brain barrier breakdown in brain ischemia: insights from MRI perfusion imaging. Neurotherapeutics. 2025;22(1):e00516. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00516.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1278_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116549","volume":"10","author":"JH Chen","year":"2015","unstructured":"Chen JH, Ke KF, Lu JH, Qiu YH, Peng YP. Protection of TGF-\u03b21 against neuroinflammation and neurodegeneration in A\u03b21-42-induced Alzheimer\u2019s disease model rats. PLoS ONE. 2015;10(2):e0116549. https:\/\/doi.org\/10.1371\/journal.pone.0116549.","journal-title":"PLoS ONE"},{"key":"1278_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30040848","author":"T Numakawa","year":"2025","unstructured":"Numakawa T, Kajihara R. The role of brain-derived neurotrophic factor as an essential mediator in neuronal functions and the therapeutic potential of its mimetics for neuroprotection in neurologic and psychiatric disorders. Molecules. 2025. https:\/\/doi.org\/10.3390\/molecules30040848.","journal-title":"Molecules"},{"issue":"15","key":"1278_CR18","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.18632\/aging.204935","volume":"15","author":"J Zhuang","year":"2023","unstructured":"Zhuang J, Cao Y, Guo G, Li M, Zhang T, He D, et al. Inhibition of BACE1 attenuates microglia-induced neuroinflammation after intracerebral hemorrhage by suppressing STAT3 activation. Aging Albany NY. 2023;15(15):7709\u201326. https:\/\/doi.org\/10.18632\/aging.204935.","journal-title":"Aging Albany NY"},{"issue":"1","key":"1278_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00278-7","volume":"11","author":"M Verma","year":"2022","unstructured":"Verma M, Lizama BN, Chu CT. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegener. 2022;11(1):3. https:\/\/doi.org\/10.1186\/s40035-021-00278-7.","journal-title":"Transl Neurodegener"},{"key":"1278_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155570","volume":"129","author":"K Liu","year":"2024","unstructured":"Liu K, Zhou Y, Song X, Zeng J, Wang Z, Wang Z, et al. Baicalin attenuates neuronal damage associated with SDH activation and PDK2-PDH axis dysfunction in early reperfusion. Phytomedicine. 2024;129:155570. https:\/\/doi.org\/10.1016\/j.phymed.2024.155570.","journal-title":"Phytomedicine"},{"key":"1278_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023. https:\/\/doi.org\/10.1038\/sigtrans.2017.23.","journal-title":"Signal Transduct Target Ther"},{"key":"1278_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040562","author":"NA Shlobin","year":"2021","unstructured":"Shlobin NA, Har-Even M, Itsekson-Hayosh Z, Harnof S, Pick CG. Role of thrombin in central nervous system injury and disease. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11040562.","journal-title":"Biomolecules"},{"issue":"3","key":"1278_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12975-020-00855-4","volume":"12","author":"F Ye","year":"2021","unstructured":"Ye F, Garton HJL, Hua Y, Keep RF, Xi G. The role of thrombin in brain injury after hemorrhagic and ischemic stroke. Transl Stroke Res. 2021;12(3):496\u2013511. https:\/\/doi.org\/10.1007\/s12975-020-00855-4.","journal-title":"Transl Stroke Res"},{"issue":"3","key":"1278_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248431","volume":"16","author":"E Shavit-Stein","year":"2021","unstructured":"Shavit-Stein E, Mindel E, Gofrit SG, Chapman J, Maggio N. Ischemic stroke in PAR1 KO mice: decreased brain plasmin and thrombin activity along with decreased infarct volume. PLoS ONE. 2021;16(3):e0248431. https:\/\/doi.org\/10.1371\/journal.pone.0248431.","journal-title":"PLoS ONE"},{"key":"1278_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9121269","author":"F Freitas","year":"2020","unstructured":"Freitas F, Tibiri\u00e7\u00e1 E, Singh M, Fraser PA, Mann GE. Redox regulation of microvascular permeability: IL-1\u03b2 potentiation of bradykinin-induced permeability is prevented by simvastatin. Antioxidants. 2020. https:\/\/doi.org\/10.3390\/antiox9121269.","journal-title":"Antioxidants"},{"issue":"4","key":"1278_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.freeradbiomed.2010.12.010","volume":"50","author":"A Woodfin","year":"2011","unstructured":"Woodfin A, Hu DE, Sarker M, Kurokawa T, Fraser P. Acute NADPH oxidase activation potentiates cerebrovascular permeability response to bradykinin in ischemia-reperfusion. Free Radic Biol Med. 2011;50(4):518\u201324. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.12.010.","journal-title":"Free Radic Biol Med"},{"key":"1278_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083883","author":"T de Los Reyes Corrales","year":"2021","unstructured":"de Los Reyes Corrales T, Losada-P\u00e9rez M, Casas-Tint\u00f3 S. JNK pathway in CNS pathologies. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22083883.","journal-title":"Int J Mol Sci"},{"key":"1278_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.764038","volume":"8","author":"XD Xia","year":"2021","unstructured":"Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038. https:\/\/doi.org\/10.3389\/fcvm.2021.764038.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"1278_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5551\/jat.55400","volume":"27","author":"E Yurtseven","year":"2020","unstructured":"Yurtseven E, Ural D, Baysal K, Tokg\u00f6zo\u011flu L. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb. 2020;27(9):909\u201318. https:\/\/doi.org\/10.5551\/jat.55400.","journal-title":"J Atheroscler Thromb"},{"issue":"9","key":"1278_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074067","volume":"13","author":"X Ye","year":"2023","unstructured":"Ye X, Wang S, Liu X, Wu Q, Lv Y, Lv Q, et al. Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta-analysis. BMJ Open. 2023;13(9):e074067. https:\/\/doi.org\/10.1136\/bmjopen-2023-074067.","journal-title":"BMJ Open"},{"issue":"1","key":"1278_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46336-2","volume":"15","author":"D Shin","year":"2024","unstructured":"Shin D, Kim S, Lee H, Lee HC, Lee J, Park HW, et al. PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor. Nat Commun. 2024;15(1):2789. https:\/\/doi.org\/10.1038\/s41467-024-46336-2.","journal-title":"Nat Commun"},{"key":"1278_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.925587","volume":"9","author":"M Palumbo","year":"2022","unstructured":"Palumbo M, Giammanco A, Purrello F, Pavanello C, Mombelli G, Di Pino A, et al. Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation. Front Mol Biosci. 2022;9:925587. https:\/\/doi.org\/10.3389\/fmolb.2022.925587.","journal-title":"Front Mol Biosci"},{"key":"1278_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.746989","volume":"8","author":"P Jin","year":"2021","unstructured":"Jin P, Gao D, Cong G, Yan R, Jia S. Role of PCSK9 in homocysteine-accelerated lipid accumulation in macrophages and atherosclerosis in ApoE(-\/-) mice. Front Cardiovasc Med. 2021;8:746989. https:\/\/doi.org\/10.3389\/fcvm.2021.746989.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"1278_CR34","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.7150\/thno.83914","volume":"13","author":"S Liu","year":"2023","unstructured":"Liu S, Wu J, Stolarz A, Zhang H, Boerma M, Byrum SD, et al. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging. Theranostics. 2023;13(9):2914\u201329. https:\/\/doi.org\/10.7150\/thno.83914.","journal-title":"Theranostics"},{"key":"1278_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11030569","author":"V Cammisotto","year":"2022","unstructured":"Cammisotto V, Baratta F, Simeone PG, Barale C, Lupia E, Galardo G, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) beyond lipids: the role in oxidative stress and thrombosis. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11030569.","journal-title":"Antioxidants"},{"key":"1278_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084114","author":"MG Lupo","year":"2021","unstructured":"Lupo MG, Marchian\u00f2 S, Adorni MP, Zimetti F, Ruscica M, Greco MF, et al. PCSK9 induces rat smooth muscle cell proliferation and counteracts the pleiotropic effects of simvastatin. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22084114.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1278_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-021-00344-0","volume":"19","author":"J Peng","year":"2021","unstructured":"Peng J, Liu MM, Liu HH, Guo YL, Wu NQ, Dong Q, et al. Association of circulating proprotein convertase subtilisin\/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study. Thromb J. 2021;19(1):90. https:\/\/doi.org\/10.1186\/s12959-021-00344-0.","journal-title":"Thromb J"},{"key":"1278_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00609","volume":"14","author":"EM O'Connell","year":"2020","unstructured":"O\u2019Connell EM, Lohoff FW. Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders. Front Neurosci. 2020;14:609. https:\/\/doi.org\/10.3389\/fnins.2020.00609.","journal-title":"Front Neurosci"},{"issue":"9","key":"1278_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100426","volume":"64","author":"AK Jaafar","year":"2023","unstructured":"Jaafar AK, Techer R, Chemello K, Lambert G, Bourane S. PCSK9 and the nervous system: a no-brainer? J Lipid Res. 2023;64(9):100426. https:\/\/doi.org\/10.1016\/j.jlr.2023.100426.","journal-title":"J Lipid Res"},{"issue":"2","key":"1278_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.010838","volume":"8","author":"N Apaijai","year":"2019","unstructured":"Apaijai N, Moisescu DM, Palee S, McSweeney CM, Saiyasit N, Maneechote C, et al. Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation. J Am Heart Assoc. 2019;8(2):e010838. https:\/\/doi.org\/10.1161\/jaha.118.010838.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1278_CR41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3233\/JAD-161136","volume":"57","author":"LS Liu","year":"2017","unstructured":"Liu LS, Bai XQ, Gao Y, Wu Q, Ren Z, Li Q, et al. PCSK9 promotes oxLDL-induced PC12 cell apoptosis through the Bcl-2\/Bax-Caspase 9\/3 signaling pathway. J Alzheimers Dis. 2017;57(3):723\u201334. https:\/\/doi.org\/10.3233\/JAD-161136.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1278_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01178-y","volume":"20","author":"SK Park","year":"2025","unstructured":"Park SK, Hwang JT, Choi HK, Lee J. Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals. Chin Med. 2025;20(1):121. https:\/\/doi.org\/10.1186\/s13020-025-01178-y.","journal-title":"Chin Med"},{"key":"1278_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100701","volume":"19","author":"M Safarova","year":"2024","unstructured":"Safarova M, Bimal T, Soffer DE, Hirsh B, Shapiro MD, Mintz G, et al. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. Am J Prev Cardiol. 2024;19:100701. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100701.","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"1278_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005639","volume":"6","author":"HE Bays","year":"2017","unstructured":"Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, et al. Alirocumab treatment and achievement of non-high-density lipoprotein cholesterol and apolipoprotein B goals in patients with hypercholesterolemia: pooled results from 10 phase 3 ODYSSEY trials. J Am Heart Assoc. 2017;6(8):e005639. https:\/\/doi.org\/10.1161\/JAHA.117.005639.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1278_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","volume":"146","author":"E Hagstr\u00f6m","year":"2022","unstructured":"Hagstr\u00f6m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab. Circulation. 2022;146(9):657\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057807.","journal-title":"Circulation"},{"issue":"2","key":"1278_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1278_CR47","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"8","key":"1278_CR48","first-page":"5129","volume":"15","author":"J Yang","year":"2023","unstructured":"Yang J, Ma X, Niu D, Sun Y, Chai X, Deng Y, et al. PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy. Am J Transl Res. 2023;15(8):5129\u201344.","journal-title":"Am J Transl Res"},{"issue":"1","key":"1278_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47242-0","volume":"9","author":"S Schuster","year":"2019","unstructured":"Schuster S, Rubil S, Endres M, Princen HMG, Boeckel JN, Winter K, et al. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. Sci Rep. 2019;9(1):11079. https:\/\/doi.org\/10.1038\/s41598-019-47242-0.","journal-title":"Sci Rep"},{"key":"1278_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065098","author":"R Zulkapli","year":"2023","unstructured":"Zulkapli R, Muid SA, Wang SM, Nawawi H. PCSK9 inhibitors reduce PCSK9 and early atherogenic biomarkers in stimulated human coronary artery endothelial cells. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24065098.","journal-title":"Int J Mol Sci"},{"key":"1278_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/life12020190","author":"MU Puteri","year":"2022","unstructured":"Puteri MU, Azmi NU, Kato M, Saputri FC. PCSK9 promotes cardiovascular diseases: recent evidence about its association with platelet activation-induced myocardial infarction. Life. 2022. https:\/\/doi.org\/10.3390\/life12020190.","journal-title":"Life"},{"issue":"18","key":"1278_CR52","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"1278_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30313-3","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Murphy SA, Kuder JF, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1278_CR54","first-page":"3586","volume":"15","author":"J Ji","year":"2023","unstructured":"Ji J, Wei X, Chen W, Wan D, Han W, Liu H. Effects of early PCSK9 inhibitor application on inflammation levels and microcirculatory function after PCI in patients with NSTE-ACS. Am J Transl Res. 2023;15(5):3586\u201396.","journal-title":"Am J Transl Res"},{"issue":"25","key":"1278_CR55","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/circulationaha.119.043826","volume":"140","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H, et al. Effect of Alirocumab on stroke in ODYSSEY OUTCOMES. Circulation. 2019;140(25):2054\u201362. https:\/\/doi.org\/10.1161\/circulationaha.119.043826.","journal-title":"Circulation"},{"issue":"12","key":"1278_CR56","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.2174\/1570159x21666230718104634","volume":"21","author":"Z Liang","year":"2023","unstructured":"Liang Z, Lou Y, Hao Y, Li H, Feng J, Liu S. The relationship of astrocytes and microglia with different stages of ischemic stroke. Curr Neuropharmacol. 2023;21(12):2465\u201380. https:\/\/doi.org\/10.2174\/1570159x21666230718104634.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"1278_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-024-04272-z","volume":"50","author":"Y Luo","year":"2024","unstructured":"Luo Y, Yuan L, Liu Z, Dong W, Huang L, Liao A, et al. Inhibition of PCSK9 protects against cerebral ischemia\u2012reperfusion injury via attenuating microcirculatory dysfunction. Neurochem Res. 2024;50(1):10. https:\/\/doi.org\/10.1007\/s11064-024-04272-z.","journal-title":"Neurochem Res"},{"issue":"1","key":"1278_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1256-8","volume":"15","author":"L Zhao","year":"2018","unstructured":"Zhao L, Chen S, Sherchan P, Ding Y, Zhao W, Guo Z, et al. Recombinant CTRP9 administration attenuates neuroinflammation via activating adiponectin receptor 1 after intracerebral hemorrhage in mice. J Neuroinflamm. 2018;15(1):215. https:\/\/doi.org\/10.1186\/s12974-018-1256-8.","journal-title":"J Neuroinflamm"},{"issue":"3","key":"1278_CR59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/hearts5030027","volume":"5","author":"ML Repp","year":"2024","unstructured":"Repp ML, Edwards MD, Burch CS, Rao A, Chinyere IR. PCSK9 inhibitors and anthracyclines: the future of cardioprotection in cardio-oncology. Hearts (Basel). 2024;5(3):375\u201388. https:\/\/doi.org\/10.3390\/hearts5030027.","journal-title":"Hearts (Basel)"},{"issue":"1\u20132","key":"1278_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11010-011-1028-6","volume":"359","author":"CY Wu","year":"2012","unstructured":"Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl\/Bax-caspase9-caspase3 pathway. Mol Cell Biochem. 2012;359(1\u20132):347\u201358. https:\/\/doi.org\/10.1007\/s11010-011-1028-6.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"1278_CR61","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s13167-017-0106-6","volume":"8","author":"M Wici\u0144ski","year":"2017","unstructured":"Wici\u0144ski M, \u017bak J, Malinowski B, Popek G, Grze\u015bk G. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017;8(4):391\u2013402. https:\/\/doi.org\/10.1007\/s13167-017-0106-6.","journal-title":"EPMA J"},{"key":"1278_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810221","author":"S Ilut","year":"2022","unstructured":"Ilut S, Pirlog BO, Pirlog R, Nutu A, Vacaras V, Armean SM. Recent advances on the roles of PCSK-9 inhibitors in the management of acute ischemic stroke patients. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231810221.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1278_CR63","doi-asserted-by":"publisher","first-page":"574","DOI":"10.5603\/CJ.a2021.0110","volume":"29","author":"Q Geng","year":"2022","unstructured":"Geng Q, Li X, Sun Q, Wang Z. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiol J. 2022;29(4):574\u201381. https:\/\/doi.org\/10.5603\/CJ.a2021.0110.","journal-title":"Cardiol J"},{"issue":"2","key":"1278_CR64","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-024-01145-5","volume":"39","author":"W Tian","year":"2025","unstructured":"Tian W, Cao H, Li X, Gong X, Yu X, Li D, et al. Adjunctive PCSK9 inhibitor evolocumab in the prevention of early neurological deterioration in non-cardiogenic acute ischemic stroke: a multicenter, prospective, randomized, open-label, clinical trial. CNS Drugs. 2025;39(2):197\u2013208. https:\/\/doi.org\/10.1007\/s40263-024-01145-5.","journal-title":"CNS Drugs"},{"issue":"11","key":"1278_CR65","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s11886-022-01782-6","volume":"24","author":"N Arnold","year":"2022","unstructured":"Arnold N, Koenig W. PCSK9 inhibitor wars: how does inclisiran fit in with current monoclonal antibody inhibitor therapy? Considerations for patient selection. Curr Cardiol Rep. 2022;24(11):1657\u201367. https:\/\/doi.org\/10.1007\/s11886-022-01782-6.","journal-title":"Curr Cardiol Rep"},{"key":"1278_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030063","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Mu\u00f1oz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018. https:\/\/doi.org\/10.3390\/diseases6030063.","journal-title":"Diseases"},{"key":"1278_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012192","author":"B Papotti","year":"2022","unstructured":"Papotti B, Adorni MP, Marchi C, Zimetti F, Ronda N, Panighel G, et al. PCSK9 affects astrocyte cholesterol metabolism and reduces neuron cholesterol supplying in vitro: potential implications in Alzheimer\u2019s disease. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232012192.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1278_CR68","doi-asserted-by":"publisher","first-page":"7310","DOI":"10.1111\/jcmm.14586","volume":"23","author":"S Palee","year":"2019","unstructured":"Palee S, McSweeney CM, Maneechote C, Moisescu DM, Jaiwongkam T, Kerdphoo S, et al. PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia\/reperfusion injury: benefits beyond lipid-lowering effects. J Cell Mol Med. 2019;23(11):7310\u20139. https:\/\/doi.org\/10.1111\/jcmm.14586.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"1278_CR69","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12325-023-02764-y","volume":"41","author":"A Alshahrani","year":"2024","unstructured":"Alshahrani A, Kholaif N, Al-Khnifsawi M, Zarif H, Mahzari M. The effect of PCSK9 inhibitors on LDL-C target achievement in patients with homozygous familial hypercholesterolemia: a retrospective cohort analysis. Adv Ther. 2024;41(2):837\u201346. https:\/\/doi.org\/10.1007\/s12325-023-02764-y.","journal-title":"Adv Ther"},{"issue":"1","key":"1278_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/strokeaha.124.048994","volume":"56","author":"N Horie","year":"2025","unstructured":"Horie N, Inoue M, Morimoto T, Sadakata E, Okamura K, Morofuji Y, et al. Recanalization does not always equate to reperfusion: no-reflow phenomenon after successful thrombectomy. Stroke. 2025;56(1):183\u20139. https:\/\/doi.org\/10.1161\/strokeaha.124.048994.","journal-title":"Stroke"},{"issue":"1","key":"1278_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47993-w","volume":"9","author":"H Kinoshita","year":"2019","unstructured":"Kinoshita H, Maki T, Yasuda K, Kishida N, Sasaoka N, Takagi Y, et al. KUS121, a valosin-containing protein modulator, attenuates ischemic stroke via preventing ATP depletion. Sci Rep. 2019;9(1):11519. https:\/\/doi.org\/10.1038\/s41598-019-47993-w.","journal-title":"Sci Rep"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01278-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01278-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:29:22Z","timestamp":1776698962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01278-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01278-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Lanlan Pu, Jiahui Liu and Shuying Kong: Conceived the article and responsible for manuscript writing. Yuki Joyama and Xing Gong: Conducted literature retrieval and conducted thematic categorization of literature across disciplines. Xiaofei Ji and Huijie Dong: Conducted the article and final review. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}